The Phase 3 trial of ALS-L1023, sponsored by Hanmi Pharmaceutical Company Limited, aimed to evaluate the efficacy and safety of the drug in patients with abdominal obesity associated with metabolic syndrome. Given the increasing prevalence of metabolic syndrome globally, particularly in developed countries, there is a significant market opportunity for effective treatments. However, the trial's termination raises concerns regarding the drug's viability and may impact Hanmi's competitive positioning in the obesity and metabolic disorder market. Stakeholders should conduct further diligence to assess the reasons for termination and explore alternative strategies or assets within Hanmi's pipeline.